The role of CCT5 in human tumors: a pan-cancer analysis

Abstract

CCT5, a molecular chaperone protein, was analyzed in 33 different tumor types by pan-cancer analysis. This study investigated various aspects such as gene expression, proteomic expression, immune infiltration, DNA methylation, genetic alterations, survival, enrichment analysis, and prognostic significance. The results showed that CCT5 is highly expressed in most tumors, and its overexpression is associated with poor overall and disease-free survival, as well as poor prognosis in different tumor types. Immune infiltration analysis revealed a correlation between CCT5, cancer-associated fibroblasts (CAFs), CD8 + T cells, and NK cells, and the prognosis of patients with different tumor types was significantly correlated with the expression of these three tumor-infiltrating immune cells. This study suggested that CCT5 regulates the number of tumor-infiltrating immune cells, thereby affecting the prognosis of these tumors. Enrichment analysis revealed the association of CCT5 with cell cycle and RNA-binding pathways. CCT5 is highly expressed in tumors, with reduced promoter and N-shore methylation, indicating its potential oncogenic and epigenetic roles. These findings suggest that CCT5 may serve as a potential prognostic biomarker and target for immunotherapy in cancer cell proliferation and development.